Cargando…
Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
AIMS : We aimed to provide contemporary real-world data on wearable cardioverter-defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance and acceptability. METHODS AND RESULTS : Across 88 French centres, the WEARIT-France study enrolled retrospectively patients who...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842091/ https://www.ncbi.nlm.nih.gov/pubmed/33257972 http://dx.doi.org/10.1093/europace/euaa268 |
_version_ | 1783643943765803008 |
---|---|
author | Garcia, Rodrigue Combes, Nicolas Defaye, Pascal Narayanan, Kumar Guedon-Moreau, Laurence Boveda, Serge Blangy, Hugues Bouet, Jérôme Briand, Florent Chevalier, Philippe Cottin, Yves Da Costa, Antoine Degand, Bruno Deharo, Jean-Claude Eschalier, Romain Extramiana, Fabrice Goralski, Marc Guy-Moyat, Benoit Guyomar, Yves Hermida, Jean-Sylvain Jourda, François Lellouche, Nicolas Mahfoud, Mohanad Manenti, Vladimir Mansourati, Jacques Martin, Angéline Pasquié, Jean-Luc Ritter, Philippe Rollin, Anne Tibi, Thierry Yalioua, Arab Gras, Daniel Sadoul, Nicolas Piot, Olivier Leclercq, Christophe Marijon, Eloi |
author_facet | Garcia, Rodrigue Combes, Nicolas Defaye, Pascal Narayanan, Kumar Guedon-Moreau, Laurence Boveda, Serge Blangy, Hugues Bouet, Jérôme Briand, Florent Chevalier, Philippe Cottin, Yves Da Costa, Antoine Degand, Bruno Deharo, Jean-Claude Eschalier, Romain Extramiana, Fabrice Goralski, Marc Guy-Moyat, Benoit Guyomar, Yves Hermida, Jean-Sylvain Jourda, François Lellouche, Nicolas Mahfoud, Mohanad Manenti, Vladimir Mansourati, Jacques Martin, Angéline Pasquié, Jean-Luc Ritter, Philippe Rollin, Anne Tibi, Thierry Yalioua, Arab Gras, Daniel Sadoul, Nicolas Piot, Olivier Leclercq, Christophe Marijon, Eloi |
author_sort | Garcia, Rodrigue |
collection | PubMed |
description | AIMS : We aimed to provide contemporary real-world data on wearable cardioverter-defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance and acceptability. METHODS AND RESULTS : Across 88 French centres, the WEARIT-France study enrolled retrospectively patients who used the WCD between May 2014 and December 2016, and prospectively all patients equipped for WCD therapy between January 2017 and March 2018. All patients received systematic education session through a standardized programme across France at the time of initiation of WCD therapy and were systematically enrolled in the LifeVest Network remote services. Overall, 1157 patients were included (mean age 60 ± 12 years, 16% women; 46% prospectively): 82.1% with ischaemic cardiomyopathy, 10.3% after implantable cardioverter-defibrillator explant, and 7.6% before heart transplantation. Median WCD usage period was 62 (37–97) days. Median daily wear time of WCD was 23.4 (22.2–23.8) h. In multivariate analysis, younger age was associated with lower compliance [adjusted odds ratio (OR) 0.97, 95% confidence interval (CI) 0.95–0.99, P < 0.01]. A total of 18 participants (1.6%) received at least one appropriate shock, giving an incidence of appropriate therapy of 7.2 per 100 patient-years. Patient-response button allowed the shock to be aborted in 35.7% of well-tolerated sustained ventricular arrhythmias and in 95.4% of inappropriate ventricular arrhythmia detection, finally resulting in an inappropriate therapy in eight patients (0.7%). CONCLUSION: Our real-life findings reinforce previous studies on the efficacy and safety of the WCD in the setting of transient high-risk group in selected patients. Moreover, they emphasize the fact that when prescribed appropriately, in concert with adequate patient education and dedicated follow-up using specific remote monitoring system, compliance with WCD is high and the device well-tolerated by the patient. |
format | Online Article Text |
id | pubmed-7842091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-78420912021-02-02 Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study Garcia, Rodrigue Combes, Nicolas Defaye, Pascal Narayanan, Kumar Guedon-Moreau, Laurence Boveda, Serge Blangy, Hugues Bouet, Jérôme Briand, Florent Chevalier, Philippe Cottin, Yves Da Costa, Antoine Degand, Bruno Deharo, Jean-Claude Eschalier, Romain Extramiana, Fabrice Goralski, Marc Guy-Moyat, Benoit Guyomar, Yves Hermida, Jean-Sylvain Jourda, François Lellouche, Nicolas Mahfoud, Mohanad Manenti, Vladimir Mansourati, Jacques Martin, Angéline Pasquié, Jean-Luc Ritter, Philippe Rollin, Anne Tibi, Thierry Yalioua, Arab Gras, Daniel Sadoul, Nicolas Piot, Olivier Leclercq, Christophe Marijon, Eloi Europace Clinical Research AIMS : We aimed to provide contemporary real-world data on wearable cardioverter-defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance and acceptability. METHODS AND RESULTS : Across 88 French centres, the WEARIT-France study enrolled retrospectively patients who used the WCD between May 2014 and December 2016, and prospectively all patients equipped for WCD therapy between January 2017 and March 2018. All patients received systematic education session through a standardized programme across France at the time of initiation of WCD therapy and were systematically enrolled in the LifeVest Network remote services. Overall, 1157 patients were included (mean age 60 ± 12 years, 16% women; 46% prospectively): 82.1% with ischaemic cardiomyopathy, 10.3% after implantable cardioverter-defibrillator explant, and 7.6% before heart transplantation. Median WCD usage period was 62 (37–97) days. Median daily wear time of WCD was 23.4 (22.2–23.8) h. In multivariate analysis, younger age was associated with lower compliance [adjusted odds ratio (OR) 0.97, 95% confidence interval (CI) 0.95–0.99, P < 0.01]. A total of 18 participants (1.6%) received at least one appropriate shock, giving an incidence of appropriate therapy of 7.2 per 100 patient-years. Patient-response button allowed the shock to be aborted in 35.7% of well-tolerated sustained ventricular arrhythmias and in 95.4% of inappropriate ventricular arrhythmia detection, finally resulting in an inappropriate therapy in eight patients (0.7%). CONCLUSION: Our real-life findings reinforce previous studies on the efficacy and safety of the WCD in the setting of transient high-risk group in selected patients. Moreover, they emphasize the fact that when prescribed appropriately, in concert with adequate patient education and dedicated follow-up using specific remote monitoring system, compliance with WCD is high and the device well-tolerated by the patient. Oxford University Press 2020-11-30 /pmc/articles/PMC7842091/ /pubmed/33257972 http://dx.doi.org/10.1093/europace/euaa268 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Garcia, Rodrigue Combes, Nicolas Defaye, Pascal Narayanan, Kumar Guedon-Moreau, Laurence Boveda, Serge Blangy, Hugues Bouet, Jérôme Briand, Florent Chevalier, Philippe Cottin, Yves Da Costa, Antoine Degand, Bruno Deharo, Jean-Claude Eschalier, Romain Extramiana, Fabrice Goralski, Marc Guy-Moyat, Benoit Guyomar, Yves Hermida, Jean-Sylvain Jourda, François Lellouche, Nicolas Mahfoud, Mohanad Manenti, Vladimir Mansourati, Jacques Martin, Angéline Pasquié, Jean-Luc Ritter, Philippe Rollin, Anne Tibi, Thierry Yalioua, Arab Gras, Daniel Sadoul, Nicolas Piot, Olivier Leclercq, Christophe Marijon, Eloi Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study |
title | Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study |
title_full | Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study |
title_fullStr | Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study |
title_full_unstemmed | Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study |
title_short | Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study |
title_sort | wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the wearit-france cohort study |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842091/ https://www.ncbi.nlm.nih.gov/pubmed/33257972 http://dx.doi.org/10.1093/europace/euaa268 |
work_keys_str_mv | AT garciarodrigue wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT combesnicolas wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT defayepascal wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT narayanankumar wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT guedonmoreaulaurence wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT bovedaserge wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT blangyhugues wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT bouetjerome wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT briandflorent wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT chevalierphilippe wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT cottinyves wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT dacostaantoine wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT degandbruno wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT deharojeanclaude wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT eschalierromain wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT extramianafabrice wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT goralskimarc wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT guymoyatbenoit wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT guyomaryves wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT hermidajeansylvain wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT jourdafrancois wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT lellouchenicolas wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT mahfoudmohanad wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT manentivladimir wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT mansouratijacques wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT martinangeline wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT pasquiejeanluc wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT ritterphilippe wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT rollinanne wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT tibithierry wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT yaliouaarab wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT grasdaniel wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT sadoulnicolas wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT piotolivier wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT leclercqchristophe wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy AT marijoneloi wearablecardioverterdefibrillatorinpatientswithatransientriskofsuddencardiacdeaththewearitfrancecohortstudy |